Post by Windward Bio

We are pleased to announce that the first patients have been dosed in the Phase 2 SIRIUS clinical trial, evaluating WIN378 in chronic obstructive pulmonary disease (#COPD). This important milestone marks an expansion of our commitment to advancing potential therapies for people living with serious immunological diseases. In this way, we continue to build on the ongoing Phase 2/3 POLARIS program, which is evaluating WIN378 in asthma. Read more: https://lnkd.in/eVz_FFzw